News

Genethon, member of the Biotherapies Institute for Rare Diseases

The Biotherapies Institute for Rare Diseases, a unique task force to accelerate therapeutic developments, includes 4 laboratories founded and supported by the AFM Telethon : the Institute of Myology, Genethon, I-Stem and Atlantic Gene Therapies (Nantes’ gene therapy research centre). (read more)

Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod

As of 2 April this year, Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon. Mr. Schwenck is a seasoned expert in manufacturing of pharmaceutical products. He began his career at Rhône Poulenc,… (read more)

Fulvio Mavilio, the internationally acknowledged expert in gene therapy for rare diseases, is appointed as Genethon’s new Scientific Director

Fulvio Mavilio, PhD (aged 58), an internationalacknowledged expert and pioneer in gene therapy for rare diseases for more than twenty years, was appointed as the new Scientific Director of Généthon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (AFM) with donations from France’s annual Telethon) on January… (read more)

Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

Evry (France), January 12, 2012 – The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain on January 11, 2012. The… (read more)

On the Internet site of the Usine Nouvelle magazine you can discover the Genethon laboratory financed by donations to the Telethon through images from behind the scenes

Both clear and comprehensive, this document will take you to the heart of gene therapy. (read more)

Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial

The US Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). After its implementation in Paris and London, this trial based on preclinical research performed at Genethon (Evry, France) which also manufactures the GMP gene therapy… (read more)

Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial

Evry (France), March 8th, 2011 – Genethon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) with donations from France’s annual Telethon) and Wake Forest University School of Medicine (Winston Salem, North Carolina, USA) today… (read more)

Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston

A unique multicenter international study of gene therapy for a rare genetic disease (Wiskott-Aldrich syndrome) led in London, Paris and Boston. (read more)

bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

Cambridge, Mass. And Evry, France, December 14, 2010 – bluebird bio (formerly Genetix Pharmaceuticals Inc.), an emerging leader in the development of innovative gene therapies for severe genetic disorders, and Généthon, a leader in the field of gene therapy treatments for rare diseases, today announced a research… (read more)

Thérapie génique – la découverte d’un mini-gène fonctionnel ouvre une nouvelle voie thérapeutique dans les dysferlinopathies

v style=”height:20px” aria-hidden=”true” class=”wp-block-spacer”> (read more)

Innovative biotherapies and genetic eye diseases

Innovative biotherapies and genetic eye diseases: the Réseau Thérapie Génique Oculaire (Ocular Gene Therapy Network) prepares to launch human trials (read more)

Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)

Généthon, the not-for-profit biotherapy laboratory operated by the French Muscular Dystrophy Association (AFM) with funding from the country’s annual Telethon*, has just obtained approval from the French and British health authorities for a Phase I/II clinical trial of gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). (read more)

Genethon appoints biopharma industry expert Frédéric Revah as Chief Executive

Genethon, the not-for-profit biotherapy research centre created by the French Muscular Dystrophy Association (AFM) and funded with donations from the country’s annual Telethon, today announced the appointment of Frédéric Revah PhD as Chief Executive. (read more)

Journée internationale Maladies Rares du 28 février 2010 : Les acteurs de la Plateforme Maladies Rares attendent un second plan français à la hauteur de enjeux

v style=”height:20px” aria-hidden=”true” class=”wp-block-spacer”> (read more)

An effective gene therapy approach for dysferlin deficiencies

Research scientists at Généthon find a solution to the problem of the dysferlin gene’s size to transport it into muscle

A team of researchers led by Isabelle Richard (CNRS UMR8587 LAMBE) in the Généthon laboratory, created and funded by AFM through Téléthon, has just demonstrated the efficacy in animals of a gene therapy strategy for… (read more)